FRM 0334

Drug Profile

FRM 0334

Alternative Names: EVP-0334; FRM0334

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator MethylGene
  • Developer EnVivo Pharmaceuticals; FORUM Pharmaceuticals; Mirati Therapeutics
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dementia
  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 30 Dec 2015 Phase-II clinical trials in Dementia (In the elderly, In adults) in Belgium, France and United Kingdom (PO)
  • 16 Nov 2014 Discontinued - Phase-I for Parkinson's disease in USA (PO)
  • 01 Oct 2014 Phase-II clinical trials in Dementia (In adults, In the elderly) in Italy and Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top